WILL HAVE A CHANCE TO SEE IT CREATE OVER THE NEXT SEVERAL CREATE OVER THE NEXT SEVERAL YEARS. I ASSUME. YEARS. I THINK. A CUSTOMER FROM HERMANTOWN NEEDS An AUDIENCE FROM HERMANTOWN INTEND TO DISCUSS THE HIGH PRICE OF TO SPEAK ABOUT THE HIGH RATE OF PHARMACEUTICALS. MEDICINES. AS WELL AS DRUGS. DRUGS. AS WELL AS WISHES TO KNOW– THE CUSTOMER WOULD LIKE TO KNOW– THE VISITOR MAKES THE OBSERVATION THAT THE MAKES THE MONITORING THAT THE GENERAL PUBLIC ADDS TO PUBLIC ADDS TO COMPANIES THAT SUPPORT COMPANIES THAT ASSISTANCE STUDY EFFORTS FOR NEW DRUGS.RESEARCH EFFORTS FOR
NEW MEDICATIONS. AND A WHOLE LOT OF ADVANCEMENT GOING AS WELL AS A LOT OF ADVANCEMENT GOING ON. SO WHY ARE THE ON. SO WHY ARE THE PHARMACEUTICAL COST SO HIGH. DRUG COSTS SO HIGH. AND ALSO WHAT CANISTER WE DO ABOUT IT? AND ALSO WHAT CAN WE DO ABOUT IT? >> > > WHY ARE THEY CHEAPER IN >> > > WHY ARE THEY CHEAPER IN CANADA? CANADA? YOU HAVE SEEN ACTIVITY AT THE YOU HAVE SEEN ACTION AT THE FEDERAL LEVEL. FEDERAL LEVEL. SENATOR ISSUE. LEGISLATOR KLOBUCHAR SENATOR ISSUE. LEGISLATOR KLOBUCHAR HAS BEEN A LEADER IN HAS BEEN A LEADER IN CHALLENGEING PRICES BY CHALLENGEING RATES BY PHARMACEUTICALS. DRUGS. IT'' S A LITTLE EVEN MORE HARD TO IT'' S A LITTLE EVEN MORE CHALLENGING TO PERFORM IT ON A STATE DEGREE. DO THIS ON A STATE LEVEL. BUT I DO NEED TO SAY THAT WE BUT I DO NEED TO SAY THAT WE CERTAINLY HAVE NOT BEEN VERY CERTAINLY HAVE NOT BEEN EXTREMELY PLEASED WITH WHAT THE SATISFIED WITH WHAT THE DRUG SECTOR DID DRUG MARKET DID AROUND OPIOIDS AS WELL AS PRODUCING A AROUND OPIOIDS AND PRODUCING An EXTREMELY SOLID PAIN RELIEVER THAT An EXTREMELY SOLID PAIN RELIEVER THAT A GREAT DEAL OF PEOPLE WERE SUGGESTED GREAT DEAL OF PEOPLE WERE SUGGESTED WITH NO EXPERTISE AS WELL AS NO WITHOUT ANY KNOWLEDGE AS WELL AS NO UNDERSTANDING HOW ADDICTIVE THEY REALIZATION HOW ADDICTIVE THEY ARE GOING TO BE.ARE GOING TO BE. IT'' S A LITTLE OFF YOUR VISITOR'' S IT ' S A LITTLE OFF YOUR CUSTOMER'' S INQUIRY. BUT WE HAVE An EXPENSE INQUIRY. BUT WE HAVE A COSTS THAT PASSED US SENATE IN 2015 ON THAT PARTICULAR PASSED US SENATE IN 2015 ON OPIOID TREATMENT AND ALSO PREVENTION. OPIOID TREATMENT AND ALSO AVOIDANCE. OPIOID ADDICTION. TREATMENT AS WELL AS OPIOID DEPENDENCY. THERAPY AS WELL AS AVOIDANCE. AS WELL AS WE THINK IT'' S AVOIDANCE. AND WE THINK IT'' S RELOCATING YOUR HOUSE NOW. RELOCATING YOUR HOME NOW. YOU GUYS CONTAINER PROBABLY DISCUSS YOU GUYS CAN PROBABLY TALK ABOUT THAT.AND I THINK THAT'' S GOING THAT'. AND ALSO I ASSUME THAT ' S GOING TO BE SIGNIFICANT REGULATION TO BE SIGNIFICANT LEGISLATION THAT WILL CERTAINLY PASS. THAT WILL CERTAINLY PASS. BUT FOR United States TO BE ABLE TO CONTROL BUT FOR US TO BE ABLE TO CONTROL THE HERE AND NOW DRUGS ON A THE EXISTING DRUGS ON A STATE DEGREE IS MORE DIFFICULT. STATE DEGREE IS EVEN MORE DIFFICULT. >> > > I GUESS THE FRUSTRATING PART >> > > I GUESS THE AGGRAVATING PART OF THAT IS WHEN YOU SEE INS WHICH OF THAT IS WHEN YOU SEE WHERE SOMEONE PURCHASES THE BUSINESS AS WELL AS SOMEONE BUYS THE BUSINESS AND ALSO TAKES A PRODUCT THAT HAS BEEN TAKES An ITEM THAT HAS BEEN PAID FOR IS A WOMAN.PAID FOR IS A WOMAN. STUDY HAS BEEN DONE. AND ALSO BEEN RESEARCH HAS BEEN DONE. AS WELL AS BEEN ON THE MARKET A VERY LONG TIME. AND ON THE MARKETPLACE A LONG TIME. AND ALSO IT'' S An AFFORDABLE COST.'AND IT ' S A PRACTICAL COST. AS WELL AS JACKS THE RATE UP A THOUSAND% JACKS THE COST UP A THOUSAND % JUST BECAUSE HE CONTAINER. EVEN IF HE CONTAINER. WE SEE THE SAME THING WITH WE SEE THE VERY SAME POINT WITH INSULIN. THAT INDIVIDUALS REQUIRED TO INSULIN. THAT PEOPLE REQUIRED TO REMAIN ALIVE AS WELL AS THAT THEY HAVE STAY ALIVE WHICH THEY HAVE JACKED THE HOPES UP ON IT. JACKED THE PRAYS UP ON IT. THAT ' S WHERE PEOPLE'OBTAIN THAT ' S WHERE PEOPLE GET AGGRAVATED AND ON THE OTHER IRRITATED AND ALSO ON THE VARIOUS OTHER HAND. COMPANIES WILL CERTAINLY ARGUE WE HAND. BUSINESS WILL CERTAINLY SAY WE REQUIREMENT THAT ADDITIONAL CASH. DUE TO THE FACT THAT REQUIREMENT THAT ADDITIONAL MONEY. BECAUSE THAT'' S OUR STUDY MONEY.AND THAT'' S OUR STUDY CASH. AND ALSO'THAT ' S WHERE WE GET ALL THE BRAND-NEW THAT ' S WHERE WE GET ALL THE BRAND-NEW DRUGS. LIFE CONSERVING DRUGS THAT WE MEDICINES. LIFE SAVING MEDICINES THAT WE HAVE. AS WELL AS I WEAR'' T KNOW IF THAT ' S HAVE. AND I WEAR ' T KNOW IF THAT ' S TRUE OR NOT. BUT AGAIN. IT HOLDS TRUE OR NOT. BUT AGAIN. IT IS FRUSTRATING WHEN YOU SEE A FEW OF FRUSTRATING WHEN YOU SEE SEVERAL OF THE POINTS THAT ARE REALLY THE THINGS THAT ARE TRULY EGREGIOUS WHEN THEY JACK THE EGREGIOUS WHEN THEY JACK THE COST UP ON AN OLD DRUG. AND ALSO COST UP ON AN OLD MEDICATION. AND THEY KNOW PEOPLE WILL CERTAINLY REQUIRE AND THEY KNOW INDIVIDUALS WILL REQUIRE AND ALSO BUY IT. AND ALSO THEY CONTAINER'' T OBTAIN THE BUY
IT.AND THEY CANISTER'' T OBTAIN THE MEDICATIONS THEY DEMAND TO KEEP THEM MEDICINES THEY REQUIREMENT TO MAINTAIN THEM ALIVE. ALIVE. >> > > Barry: SENATOR VOGEL. >> > > Barry: LEGISLATOR VOGEL. >> > >'IT ' S ONE OF THOSE >> POINTS I > > IT ' S AMONG THOSE THINGS I TIN ' T UNDERSTAND THE INTERNATIONAL CANISTER ' T UNDERSTAND THE INTERNATIONAL ECONOMICS ON THIS. ECONOMICS ON THIS. WHY ARE THEY DIFFERENTLY PRICED WHY ARE THEY IN DIFFERENT WAYS PRICED FROM CANADA? FROM CANADA? WHY ARE THEY IN DIFFERENT WAYS PRICED WHY ARE THEY DIFFERENTLY PRICED IN EUROPE AND ALSO WHY ARE WE IN EUROPE AND ALSO WHY ARE WE INVESTING ALL THE CASH FOR THE INVESTING ALL THE CASH FOR THE RESEARCH TO DEVELOP THESE? STUDY TO CREATE THESE? SINCE I CAN UNDERSTAND FROM DUE TO THE FACT THAT I TIN UNDERSTAND FROM THE MEDICINE FIRM'' S PERSPECTIVE THE DRUG COMPANY ' S VIEWPOINT AS WELL. ALSO. THEY HAVE A TREMENDOUS QUANTITY OF THEY HAVE A TREMENDOUS AMOUNT OF RESEARCH STUDY AS WELL AS PRICE STUCK INTO RESEARCH AND EXPENSE STUCK INTO THIS THING.AND YOU OBTAIN
TO THE THIS POINT. AND ALSO YOU OBTAIN TO THE END OF IT AND IT DOESN'' T FUNCTION OR END OF'IT AS WELL AS IT DOESN ' T WORK OR IS NOT ACCEPTED. AND ALSO YOU JUNK IS NOT ACCEPTED. AS WELL AS YOU DITCH MILLIONS OF DOLLARS. NUMEROUS DOLLARS. SO LIKE I CLAIMED. I PUT ON'' T SO LIKE I SAID. I PUT ON ' T UNDERSTAND THE ECONOMICS AS WELL AS I UNDERSTAND THE BUSINESS ECONOMICS AS WELL AS I ASSUME THAT ' S REALLY IN WHICH THE THINK THAT ' S REALLY WHERE THE CONVERSATION HAS TO START IS DISCUSSION NEEDS TO BEGIN IS WHAT ' S GOING ON IN THIS WHAT ' S GOING ON'IN THIS INDUSTRY. SINCE THERE ' S INDUSTRY. DUE TO THE FACT THAT THERE ' S SOME WONDERFUL THINGS TAKING PLACE SOME WONDERFUL THINGS TAKING PLACE AVAILABLE THAT CANISTER BE DEALT WITH AROUND THAT CONTAINER BE TREATED NOW THAT WHEN I WAS MATURING SINCE WHEN I WAS GROWING UP YOU WOULD HAVE NEVER THOUGHT OF YOU WOULD HAVE NEVER THOUGHT OF TREATING. TREATING. SOMEONE STUCK THE MONEY INTO SOMEBODY STUCK THE CASH INTO THE RESEARCH.THE RESEARCH STUDY.
BUT HOW DID IT GET SO OUT OF BUT HOW DID IT GET SO OUT OF SMACK THAT YOU COULD GO THROUGHOUT STRIKE THAT YOU COULD CROSS THE THE BOUNDARIES AS WELL AS ACQUIRE FOR A THE THE BOUNDARIES AND ALSO PURCHASE FOR A DIFFERENT RATE AND WHY. DIFFERENT RATE AND WHY. THAT'' S WHAT I WEAR ' T UNDERSTAND. THAT ' S WHAT I PUT ON ' T UNDERSTAND. ALSO I HAVE REAL TROUBLES LIKEWISE I HAVE ACTUAL PROBLEMS WITH ANY SORT OF COST CONTROLS. WITH ANY TYPE OF RATE CONTROLS. AND ALSO I TRULY BELIEVES WHEN WE DO AND ALSO I TRULY ASSUMES WHEN WE DO SOMETHING LIKE THAT WE COLLECTION SOMETHING LIKE THAT WE COLLECTION OURSELVES UP FOR A LONG-LASTING OURSELVES UP FOR A LONG-TERM CONCERN. CONCERN. DUE TO THE FACT THAT THEN YOU START BECAUSE AFTER THAT YOU BEGIN MANIPULATING WHERE IT'' S GOING TO MANIPULATING WHERE IT'' S GOING TO OBTAIN SOLD. DUE TO THE FACT THAT'IF YOU TIN ' T OBTAIN SOLD. SINCE IF YOU CAN ' T MARKET IT FOR A COST HERE.IT ' S SELL IT FOR A RATE RIGHT HERE. IT'' S GOING TO GET SOLD. GOING TO GET SOLD. IT ' S SIMPLY NOT GOING TO OBTAIN SOLD IT ' S JUST NOT GOING TO OBTAIN SOLD BELOW. RIGHT HERE. AS WELL AS WE RESEARCH STUDY THE ECONOMICS. >> AND ALSO WE'STUDY THE BUSINESS ECONOMICS. > > THERE ' S >> TALK CONCERNING TWO DECADES > > THERE ' S DISCUSS TWENTY YEARS EARLIER REGARDING RATES. AGO ABOUT RATES. SO IF YOU CONTAINER HAVE A GREAT DEAL OF SO IF YOU CAN HAVE A GREAT DEAL OF BUYERS. LIKE A STATE DOES. IF CUSTOMERS. LIKE A STATE DOES. IF YOU COULD AS A STATE DISCUSS YOU COULD AS A STATE BARGAIN WITH MEDICINE FIRMS A DECREASED WITH DRUG FIRMS A REDUCED RATE FOR THIS SPECIFIC MEDICINE. PRICE FOR THIS SPECIFIC MEDICATION. I PEEN. MEAN. I THINK IT HAPPEH I PEEN. MEAN. I ASSUME IT HAPPEH THE VETERANS MANAGEMENT OR THE VETERANS ADMINISTRATION OR FIRMS LIKE THAT WHERE THEY BUSINESS LIKE THAT WHERE THEY CONTAINER DISCUSS A LOWER PRICE.BUT CONTAINER NEGOTIATE A LOWER RATE. BUT IF YOU ARE SIMPLY AN INDIVIDUAL IF YOU ARE JUST AN INDIVIDUAL CUSTOMER. YOU JUST WEAR'' T HAVE THAT PURCHASER. YOU JUST PUT ON'' T HAVE THAT MUCH POWER IN THE MARKET. MUCH POWER IN THE MARKETPLACE. >> > > Barry: ON THE OPIOIDS BILL >> > > Barry: ON THE OPIOIDS BILL THAT SENATOR PAPPAS DISCUSSED THAT LEGISLATOR PAPPAS MENTIONED THAT WAS RELOCATING YOUR HOME. THAT WAS MOVING IN YOUR HOUSE. ANY UPDATES ON THAT? ANY UPDATES ON THAT PARTICULAR? >> > > I WEAR ' T OFFER ON THE >> HEALTH AND WELLNESS > > I WEAR ' T OFFER ON THE HEALTH AND WELLNESS AND ALSO HUMAN SERVICES COMMITTEE.SO AND ALSO HUMAN BEING SOLUTIONS BOARD. SO I HAVEN ' T SEEN IT MYSELF.'I HAVEN'' T SEEN IT MYSELF. ALTHOUGH MY LEGISLATOR IS A BIG ALTHOUGH MY SENATOR IS A BIG ADVOCATES OF THAT. SUPPORTER OF THAT. SENATOR EATON IS A COAUTHOR OF SENATOR EATON IS A COAUTHOR OF THAT BECAUSE SHE HAD A DAUGHTER THAT BECAUSE SHE HAD A DAUGHTER THAT PASSED AWAY FROM A MEDICATION THAT DIED FROM A MEDICINE OVERDOSE. AS WELL AS IT'' S SOMETHING'OVERDOSE. AS WELL AS IT ' S SOMETHING SHE ' S PASSIONATE ABOUT. SHE ' S PASSIONATE ABOUT. I DON ' T KNOW. I DON ' T KNOW. LIKE I SAID. WE WILL SEE WHAT LIKE I SAID. WE WILL SEE WHAT THEY KNOW. I ASSUME IT ' S ACQUIRING THEY KNOW. I THINK IT ' S OBTAINING A METHOD TO FUND IT. OBTAINING A MEANS A MEANS TO FUND IT. OBTAINING A METHOD TO FUND THE TREATMENT NEEDED FOR TO FUND THE TREATMENT NEEDED FOR THAT.
THAT. A PENDING EXPENSE LAST YEAR.THEY A PENDING COSTS IN 2015. THEY DOT A VARIOUS FINANCING DOT A VARIOUS FUNDING DEVICE THIS YEAR. AND ALSO I PUT ON'' T DEVICE THIS YEAR. AS WELL AS I DON'' T KNOW EVERYTHING MUCH ABOUT IT. KNOW ALL THAT MUCH ABOUT IT. ASIDE FROM INSURER BESIDES INSURANCE PROVIDER AS WELL AS MEDICATION FIRMS HAVE OPPOSED AND ALSO MEDICATION BUSINESS HAVE ACTUALLY OPPOSED EVERY WAY OF TRYING TO FUND IT. EVERY MEANS OF TRYING TO FUND IT. DUE TO THE FACT THAT THEY DON'' T INTEND TO HAVE BECAUSE THEY DON'' T WANT TO HAVE TO PAY FOR IT. WHICH IS A.
